Hernandez, A. A., Cobo, M., Cantero, A., Calles, A., Álvarez, R. Ã., Azkarate, A., Fabregat, R. M., Agüero, E., Martinez-Bueno, A., González-Cao, M., Sullivan, I. G., Vila, M. A. M., Rosell, R. (2025). Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8604